The antiretroviral combination of lopinavir/ritonavir has no significant mortality benefit in hospitalised COVID-19 patients, preliminary results from the RECOVERY trial show. The findings come after a routine review of emerging data by the independent Data Monitoring Committee led them to recommend that the chief investigators be unblinded to the results for the lopinavir-ritonavir arm. Overall, ...
Antiretroviral combination has no effect on COVID-19 outcomes
By Nicola Garrett
1 Jul 2020